Imagine the liver as a factory that produces too many 'bad' fats and inflammatory signals, leading to heart disease and diabetes. This project creates a smart delivery system, like a GPS-guided package, that carries genetic instructions to shut down those specific bad production lines. By cleaning up the liver's output, it helps prevent heart attacks and strokes.
Cardiovascular disease and diabetes are massive economic burdens, costing the EU over €210 billion annually. Current treatments often fail to address the shared liver-based mechanisms that drive these co-existing conditions.
A set of RNA-LNP formulations (siRNA pools and synthetic mRNAs) targeting liver ceramides and inflammation, validated in mouse models with a completed toxicology dossier for the EMA.
If you are a biotech drug developer dealing with the high failure rate of metabolic drugs — this project developed RNA-LNP formulations that target shared mechanisms between ASCVD, diabetes and NAFLD. This allows for a unified treatment approach rather than treating each condition separately.
If you are a clinic dealing with patients who have co-existing obesity and liver failure — this project developed a therapy to reduce lipid and inflammation load. This could lower the risk of acute clinical complications like myocardial infarction.
If you are a manufacturer dealing with the difficulty of delivering RNA to specific organs — this project developed human-approved liver-targeting lipid nanoparticles (LNP). This provides a validated delivery vehicle for RNA-based cardiometabolic therapies.
Based on available project data, no specific pricing or cost-per-dose information is provided.
The project uses established human-approved lipid nanoparticles (LNP), which suggests a path toward scaling, but specific industrial manufacturing volumes are not mentioned.
Based on available project data, the project aims to prepare a preclinical evaluation dossier for the EMA, but specific patent or licensing terms are not listed.
The project period runs from 2022-05-01 to 2027-04-30, with the goal of preparing a dossier for the European Medicines Agency (EMA).
These new treatments are designed to complement current medications offered to patients suffering from metabolic disease to improve outcomes.
The consortium is well-balanced for translational research, consisting of 9 partners across 8 countries. With a 33% industry ratio (3 industrial partners, including 2 SMEs), the project bridges the gap between 4 universities and 1 research institute, ensuring that the academic discovery of ceramide pathways is paired with industrial expertise in LNP formulation and toxicology.
Contact TAMPEREEN KORKEAKOULUSAATIO SR in Finland
Contact us to explore licensing opportunities for these RNA-LNP formulations.
